NCT06786299View on ClinicalTrials.gov

Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions
Relapsed/Refractory Acute Myeloid Leukemia(AML)
Interventions
BIOLOGICAL

RD-IIT-001

Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy

DRUG

CD84-CART

Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy

Trial Locations (1)

310003

No. 79, Qingchun Road, Hangzhou City, Zhejiang Province., Hangzhou

Sponsors

Collaborators (1)

BRL Medicine Inc.
All Listed Sponsors
collaborator

BRL Medicine Inc.

UNKNOWN

lead

First Affiliated Hospital of Zhejiang University

OTHER